We sell nothing.
That's the point.
Genexis Health Ltd. publishes summaries of the published research on peptides and related compounds — what the studies found, what they didn't, and how far apart those two things often are.
Why this exists
If you search for almost any compound on this site, you will find two kinds of page. Sellers, who have an obvious reason to emphasise what looks promising. And forum threads, where a rodent study and a phase 3 trial get cited in the same sentence with the same confidence.
What is genuinely hard to find is a plain answer to the first question anyone should ask: how much do we actually know about this, and how do we know it?
That question has real answers, and they differ enormously. Semaglutide has been tested in tens of thousands of people across multi-year trials with published cardiovascular outcomes. BPC-157, which is discussed with comparable certainty, has never been through a published controlled trial in humans for anything it is used for. Both get described as "peptides", and the word does the same work in both sentences while meaning something completely different.
What we do
18 compounds, each with a graded evidence summary. What it is, how it is thought to work, what studies have found, what they have not, the reported risks, and where it stands with regulators. The primary literature is linked throughout, so you can check our reading against the source rather than trusting us.
Grades run from "approved medicine" down to "laboratory studies only", with a separate grade for compounds that were tested in humans and failed. That last one matters: a failed trial is stronger evidence than no trial, it just points the other way, and it is information you will not get from anyone selling the compound.
What we don't do
We do not publish dosing, administration routes or protocols, and we will not provide them if asked. That is the line between an information resource and something that guides use, and we stay on the information side of it.
We do not sell, supply or broker anything. We take no advertising and have no affiliate arrangements. Nobody pays for a mention, and there is no version of a good review here that benefits us.
And we do not tell anyone what to do. Several compounds described here are prescription medicines; several more are investigational products no regulator has approved. If you are weighing any of them up, that conversation belongs with a doctor who knows your history — not with a website, and not with a supplier.
Four commitments
We sell nothing
No stock, no orders, no price list, no affiliate links. An information resource with something to sell is an advertisement, and readers are right to discount it. Removing the commercial interest is what makes the rest of this credible.
Limitations get equal billing
Every compound page has a section headed "what the evidence does not show", laid out as prominently as the findings. If the honest summary of something is that almost nothing is known, the page says that.
We report failures
Compounds that went into human trials and did not work are graded as failed. AOD-9604 did not beat placebo. Ipamorelin missed its endpoint. Nobody selling those has any reason to tell you.
We would rather be corrected
We are reading the same literature as everyone else and we will get things wrong. Send us the study. If you are right, the page changes.
Information only. Everything on this site is a summary of published research, provided for general information. It is not medical advice, not a treatment recommendation, and not a substitute for consultation with a qualified healthcare professional. Genexis Health does not sell, supply or arrange the supply of any compound described here. Many of the compounds covered are prescription-only medicines, investigational products that no regulator has approved, or substances regulators have issued public warnings about. Nothing here should be read as suggesting any of them is safe or appropriate for you to use.